Biomunex Pharmaceuticals, a Paris and Cambridge, Massachusetts-based biopharmaceutical company focused on bispecific and multi-specific antibody immunotherapies, has announced two separate research collaborations with AI-driven companies Gordion Bioscience and Tangramed Biotech to identify novel bispecific target combinations in oncology. Financial terms were not disclosed for either agreement.
The collaborations center on Biomunex’s BiXAb platform, a plug-and-play bispecific and multi-specific antibody engineering technology that generates bispecific constructs from pairs of monoclonal antibodies using proprietary in silico modeling. Under the Gordion Bioscience collaboration, the US-based partner will apply its patient-derived biological network analysis and computational target discovery capabilities to surface co-essential target pairs that conventional expression-based approaches do not detect. Tangramed Biotech, based in France, will contribute a multimodal target-combination discovery platform powered by biomedical data analytics and generative AI, with a focus on actionable target combinations in solid tumors and hematological malignancies. Both agreements are research-stage and do not involve the licensing or transfer of a specific drug candidate.
Both collaborations are structured as early discovery research agreements, with no upfront payments, milestones, royalties, or territorial terms disclosed. The arrangements appear to function as exchange-based or in-kind partnerships in which Biomunex provides its antibody engineering platform and scientific framework while each AI partner contributes computational discovery outputs. Biomunex retains responsibility for downstream preclinical and clinical development of any candidates emerging from the target identification work.
Biomunex has previously out-licensed BiXAb-derived assets under full commercial agreements, including an exclusive global licensing deal with Ipsen in December 2024 covering BMX-502, a MAIT cell-engaging bispecific antibody targeting GPC3 in solid tumors, in a deal valued at up to USD 610 million. The current AI-focused agreements represent an earlier-stage layer of the same platform strategy, feeding novel target pairs into the BiXAb pipeline rather than commercializing existing candidates.
This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/